BMY - AbbVie buyout Cerevel posts late-stage win for Parkinson's disease drug
2024-04-18 07:00:23 ET
More on AbbVie
- AbbVie: Through Humira's Crisis Towards Solid Growth
- AbbVie: Great To Be Proven Wrong - Still Not A Buy
- AbbVie: Bulletproof Fundamentals
- CVS favors Humira copycats hurting AbbVie’s market share: Evercore
- AbbVie to develop long-acting injectables in a deal worth up to $1.9B